GLP-1 insurance and Medicare coverage in 2026

GLP-1 insurance coverage is one of the fastest-moving areas in US healthcare. In 2024, most Medicare beneficiaries had no coverage for anti-obesity medications. By July 2026, a new federal bridge program will offer Wegovy and Zepbound at $50 per month for qualifying Part D enrollees. Commercial coverage is expanding but remains inconsistent. This guide explains the current landscape so you know what to expect before choosing a program.

Medicare: the GLP-1 Bridge program (July 2026)

The Medicare GLP-1 Bridge program launches July 1, 2026 and runs through December 31, 2026. It covers Wegovy and Zepbound at $50 per month for eligible Medicare Part D enrollees who meet prior authorization criteria. This is the first time Medicare has broadly covered GLP-1 medications specifically for weight management.

• Eligibility requires enrollment in a Medicare Part D plan and meeting clinical prior authorization criteria (BMI thresholds and comorbidity documentation).

• The $50/month cost applies regardless of the drug's list price — Medicare absorbs the difference.

• Coverage transitions to the BALANCE Model starting January 2027, which extends the $50/month pricing as a permanent program.

• A Medicaid component of the BALANCE Model may launch as early as May 2026, though state-by-state participation will vary.

Medicare Part D: what was covered before the Bridge

Before the Bridge program, Medicare Part D excluded anti-obesity medications by statutory definition. GLP-1 drugs were only covered under Part D for their diabetes indications (Ozempic, Mounjaro) or for the cardiovascular risk reduction indication (Wegovy, based on the SELECT trial). Patients seeking weight-management coverage had to pay entirely out of pocket or use manufacturer savings programs — which explicitly exclude Medicare beneficiaries.

Commercial insurance: the current state

Commercial insurance coverage for GLP-1 weight-management drugs varies dramatically by employer and plan. Key patterns:

• Approximately 1 in 5 large employers cover GLP-1s specifically for the weight-loss indication (KFF 2025 Employer Health Benefits Survey).

• Many more plans cover semaglutide and tirzepatide for type 2 diabetes but explicitly exclude the weight-management indication.

• Prior authorization is nearly universal — expect to document BMI, comorbidities, and sometimes evidence of prior lifestyle intervention.

• Step therapy requirements are common: some plans require documented failure of lifestyle changes or other medications before approving a GLP-1.

• Some employers dropped GLP-1 weight-loss coverage starting January 2026 due to cost pressure, while others expanded it.

• Copays and coinsurance vary widely even among plans that cover these drugs, from $25/month with manufacturer savings cards to $300+ without.

Manufacturer savings cards: who qualifies

Both Novo Nordisk (Wegovy) and Eli Lilly (Zepbound, Foundayo) offer savings card programs that reduce out-of-pocket costs for commercially insured patients. Typical terms:

• Wegovy savings card: pay as little as $25 per fill with qualifying commercial insurance. Maximum savings of $100/month. Excluded: Medicare, Medicaid, TRICARE, VA, and all government insurance.

• Zepbound savings card: pay as little as $25 per fill with qualifying commercial insurance. Annual cap of $1,300 in savings. Same government insurance exclusions.

• Foundayo savings card: $25/month with commercial insurance. Medicare Part D patients may access for $50/month beginning July 1, 2026.

Cash-pay and self-pay options

For patients without insurance coverage, several direct-to-consumer options exist:

• Wegovy injection via NovoCare Pharmacy: as low as $349/month self-pay.

• Wegovy pill via NovoCare: $149/month for lower doses, $299/month for the 25 mg maintenance dose.

• Zepbound via LillyDirect: $299/month (2.5 mg), $399/month (5 mg), $449/month (7.5-15 mg). Must refill within 45 days.

• Foundayo via LillyDirect: starting at $149/month for the lowest dose.

Questions to ask your insurance before starting

• Does my plan cover Wegovy/Zepbound specifically for weight management, or only for diabetes?

• What prior authorization documentation is required?

• Is step therapy required? If so, what must I try first?

• What is my copay or coinsurance at the covered tier?

• Am I eligible for the manufacturer savings card in addition to my insurance?

• If my plan does not cover weight-management GLP-1s, what are my appeal options?